{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:53:28Z","timestamp":1773359608098,"version":"3.50.1"},"reference-count":38,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:p>Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a second-line option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time.<\/jats:p>","DOI":"10.7224\/1537-2073.2012-031","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T16:40:44Z","timestamp":1373560844000},"page":"66-72","source":"Crossref","is-referenced-by-count":13,"title":["Advances in the Management of Neurogenic Detrusor Overactivity in Multiple Sclerosis"],"prefix":"10.7224","volume":"15","author":[{"given":"Gael J.","family":"Yonnet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette S.","family":"Fjeldstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel G.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020071713462583900_i1537-2073-15-2-66-b1","first-page":"197","article-title":"Management of urinary and bowel dysfunction in multiple sclerosis","author":"Kim","year":"2011","journal-title":"Primer on Multiple Sclerosis"},{"key":"2020071713462583900_i1537-2073-15-2-66-b2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hch105","article-title":"What drives quality of life in multiple sclerosis?","volume":"97","author":"Hemmet","year":"2004","journal-title":"QJM."},{"key":"2020071713462583900_i1537-2073-15-2-66-b3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s004150050508","article-title":"Urinary, faecal and sexual dysfunction in patients with multiple sclerosis","volume":"246","author":"Hennessey","year":"1999","journal-title":"J Neurol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/jnnp.56.3.245","article-title":"Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis","volume":"56","author":"Betts","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2020071713462583900_i1537-2073-15-2-66-b5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"De S\u00e8ze","year":"2007","journal-title":"Mult Scler."},{"key":"2020071713462583900_i1537-2073-15-2-66-b6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2990.1978.tb00555.x","article-title":"The cervical cord in multiple sclerosis","volume":"4","author":"Oppenheimer","year":"1978","journal-title":"Neuropathol Appl Neurobiol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b7","first-page":"159","article-title":"Urologic dysfunction in patients with multiple sclerosis","volume":"8","author":"Blaivas","year":"1988","journal-title":"Semin Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b8","first-page":"1059","article-title":"Neurogenic and faecal incontinence","author":"Wyndaele","year":"2005","journal-title":"Incontinence"},{"key":"2020071713462583900_i1537-2073-15-2-66-b9","first-page":"CD004193","article-title":"Anticholinergics for urinary symptoms in multiple sclerosis","volume":"1","author":"Nicholas","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"2020071713462583900_i1537-2073-15-2-66-b10","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.juro.2007.08.032","article-title":"Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder","volume":"178","author":"Neel","year":"2007","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b11","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults (review)","volume":"3","author":"Hay-Smith","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071713462583900_i1537-2073-15-2-66-b12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0163-7258(96)00091-5","article-title":"Botulinum toxin as a therapeutic agent","volume":"72","author":"Tsui","year":"1996","journal-title":"Pharmacol Ther."},{"key":"2020071713462583900_i1537-2073-15-2-66-b13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"Simpson","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2020071713462583900_i1537-2073-15-2-66-b14","doi-asserted-by":"crossref","first-page":"11516","DOI":"10.1016\/S0021-9258(19)50230-7","article-title":"Botulinum neurotoxin serotype-F is a zinc endopeptidase specific for VAMP\/synaptobrevin","volume":"268","author":"Schiavo","year":"1993","journal-title":"J Biol Chem."},{"key":"2020071713462583900_i1537-2073-15-2-66-b15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1074\/jbc.M209821200","article-title":"Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A: basis for distinct durations of inhibition of exocytosis in central neurons","volume":"278","author":"Foran","year":"2003","journal-title":"J Biol Chem."},{"key":"2020071713462583900_i1537-2073-15-2-66-b16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med."},{"key":"2020071713462583900_i1537-2073-15-2-66-b18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","article-title":"Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK center","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","article-title":"Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results","volume":"55","author":"Giannantoni","year":"2009","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand J Eurol Nephrol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","article-title":"Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections","volume":"53","author":"Gam\u00e9","year":"2008","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder\u2014to include or exclude the trigone? a prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid","year":"2010","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/01.ju.0000108120.28291.eb","article-title":"Electrical characteristics of suburothelial cells isolated from the human bladder","volume":"171","author":"Sui","year":"2004","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/jphysiol.2004.065136","article-title":"Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+ signals in detrusor smooth muscles of the guinea-pig urinary bladder","volume":"559","author":"Hashitani","year":"2004","journal-title":"J Physiol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1464-410X.2002.02834.x","article-title":"Gap junctions and connexin expression in human suburothelial interstitial cells","volume":"90","author":"Sui","year":"2002","journal-title":"BJU Int."},{"key":"2020071713462583900_i1537-2073-15-2-66-b28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.mou.0000172393.52857.92","article-title":"Recent advances in basic science for overactive bladder","volume":"15","author":"Kumar","year":"2005","journal-title":"Curr Opin Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2006.01.005","article-title":"Patel A: Botulinum toxin\u2014new mechanisms, new therapeutic directions?","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b31","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injections for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/nau.20624","article-title":"Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity","volume":"28","author":"Bach","year":"2009","journal-title":"Neurourol Urodynam."},{"key":"2020071713462583900_i1537-2073-15-2-66-b33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.sc.3101593","article-title":"Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor","volume":"42","author":"Schurch","year":"2004","journal-title":"Spinal Cord."},{"key":"2020071713462583900_i1537-2073-15-2-66-b34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.urology.2010.09.036","article-title":"Intravesical electromotive botulinum toxin type A administration: Part I\u2014experimental study","volume":"77","author":"Kajbafzadeh","year":"2011","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.urology.2010.06.003","article-title":"Intravesical electromotive botulinum toxin type A administration: Part II\u2014clinical application","volume":"77","author":"Kajbafzadeh","year":"2011","journal-title":"J Urol."},{"key":"2020071713462583900_i1537-2073-15-2-66-b36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","article-title":"What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?","volume":"97","author":"Ruffion","year":"2006","journal-title":"BJU Int."},{"key":"2020071713462583900_i1537-2073-15-2-66-b37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","article-title":"Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity","volume":"40","author":"Wyndaele","year":"2002","journal-title":"Spinal Cord."},{"key":"2020071713462583900_i1537-2073-15-2-66-b38","first-page":"499","article-title":"Are botulinum-A toxin injections into the detrusor of patients with neurogenic detrusor overactivity safe? ultrastructural data of detrusor biopsies","volume":"22","author":"Haferkamp","year":"2003","journal-title":"Neurourol Urodynam."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/15\/2\/66\/2553362\/1537-2073_2012-031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/15\/2\/66\/2553362\/1537-2073_2012-031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:30Z","timestamp":1752786750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/advances-in-the-management-of-neurogenic-detrusor-overactivity-in-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2012-031","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}